Moteur de recherche d’entreprises européennes
Financement de l’UE (9 994 384 €) : Stratification basée sur le microbiome des personnes à risque de contracter le VIH-1, de complications cliniques chroniques, de résistance aux médicaments … Hor01/01/2020 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
Stratification basée sur le microbiome des personnes à risque de contracter le VIH-1, de complications cliniques chroniques, de résistance aux médicaments antimicrobiens et d’absence de réponse à la vaccination thérapeutique contre le VIH-1
The HIV/AIDS pandemic continues to be one of the major health challenges ever faced by mankind. Far from being resolved, HIV is soaring in Eastern Europe (60% increase in new infections and 27% increase in deaths since 2010) and other regions of the world despite increasing access to antiretroviral treatment. There is emerging evidence that the human microbiome impacts some of the most important clinical aspects of HIV-1 infection, including immune disorders, chronic inflammation and accelerated aging. Work in other viral diseases and cancer immunotherapy suggest a critical role of the human microbiome also in the outcome of immune therapeutic interventions in HIV-1 infection. The MISTRAL project brings together a team of world-class HIV and microbiome researchers and SMEs with ideal complementary knowledge and expertise. This team will work to discover and validate novel gut microbiome biomarkers to inform rationally-designed, mechanistically-driven interventions on the gut microbiome to mitigate HIV-1 acquisition, systemic inflammation, chronic clinical complications, antimicrobial drug resistance, and boost the efficacy of HIV cure immunotherapies. Integrated and curated large microbiome and host datasets generated during the execution of the project will be made public through a freely accessible, specifically-dedicated web-based repository. Biomarker discoveries will be incorporated into a cloud-based software tool that will automate microbiome analyses and interpretations, thus streamlining patient stratification for clinical and research purposes. If successful, MISTRAL will benefit millions of human beings living with, or at risk of acquiring HIV-1 infection, and will produce novel concepts and technical innovations applicable to other human diseases. By doing that, MISTRAL will help to unlock the full clinical potential of the human microbiome to stratify patient outcomes and will irreversibly bring microbiome science closer to clinical practice.
| Aelix Therapeutics SL | 534 979 € |
| Asphalion SL | 141 188 € |
| Case Western Reserve University Corporation | 821 560 € |
| Emory University NON Profit Corp | 732 489 € |
| Fundacio de Recerca Clinic Barcelona-Institut D Investigacions Biomediques August Pi i Sunyer | 473 431 € |
| Fundacion Privada Instituto de Salud Global Barcelona | 471 084 € |
| Fundacio Privada Institut de Recerca Sobre Immunopatologies-Caixa, Irsicaixa | 3 935 581 € |
| Hospital Clinic de Barcelona | 0,00 € |
| Karolinska Institutet | 719 572 € |
| Mediterranee Infection | 0,00 € |
| Projecte Dels Noms - Hispanosida Asociacion | 236 738 € |
| Region Hovedstaden | 1 097 611 € |
| Universite d'AIX Marseille | 730 470 € |
| Vedanta Biosciences Inc. | 99 682 € |
https://cordis.europa.eu/project/id/847943
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.
